Detailed Narrative
International Commercial Progress and Market Access
Krystal is observing strong commercial momentum for VYJUVEK in Europe and Japan, marked by increasing patient inclusions and treatment volumes. The company is actively engaged in pricing and reimbursement discussions across Germany, Italy, Spain, and the U.K., with France expected to progress into 2027. Regulatory milestones include MHRA marketing authorization in the U.K. and multiple additional submissions planned for Switzerland and Australia, despite challenges like fragmented care in Germany and GMO classification requirements in France.
U.S. Commercial Strategy and Patient Engagement
U.S. net revenue for VYJUVEK reached $91.6 million, supported by over 730 reimbursement approvals, exceeding the initial 60% penetration target of the diagnosed DEB patient population. The commercial team is expanding its reach into community settings and enhancing patient engagement through virtual education, peer-to-peer programs like VYJUVEK Voices and VYJUVEK Connections, and partnerships with Debra America, adapting to evolving patient needs for wound care management.
Ocular Pipeline Advancements: KB803 and KB801
The company is nearing readouts for two registrational studies in ocular indications. The ELITE study for KB803 in DEB ocular lesions was fully enrolled in April and is on track for a readout later this year, with BLA submission expected rapidly upon success. The Emerald One study for KB801 in Neurotrophic Keratitis (NK) is expected to complete enrollment before year-end, with data readout soon thereafter, leveraging the HSV-1 vector platform for repeat administration in the eye.
Rare Disease Pipeline: Cystic Fibrosis and Hailey-Hailey Disease
KB407 for Cystic Fibrosis and KB111 for Hailey-Hailey disease are progressing with open-label, single-arm repeat dose studies. Interim results for both programs, involving 5 CF patients and 7 Hailey-Hailey patients, are expected before year-end. The company is collaborating with the FDA and patient foundations to finalize registrational study designs, with starts planned for 2027, aiming to address significant unmet needs in these patient populations.
Oncology Pipeline: KB707 Program
Krystal's oncology pipeline, centered on KB707, is advancing. The inhaled KB707 formulation for NSCLC showed a 36% response rate as monotherapy and 31% in combination with pembrolizumab in late-line patients. Completion of the final dose expansion cohort (with chemotherapy) is expected later this year, leading to a registrational study start in 2027. Additionally, the intratumoral KB707 formulation is being evaluated in Gorlin Syndrome, a rare skin indication, with clinical updates anticipated later this year.